about
Clinical perspectives of TRAIL: insights into central nervous system disordersThe Active Metabolite of Warfarin (3'-Hydroxywarfarin) and Correlation with INR, Warfarin and Drug Weekly Dosage in Patients under Oral Anticoagulant Therapy: A Pharmacogenetics StudyDose-dependent neuroprotection of VEGF₁₆₅ in Huntington's disease striatumFamilial amyotrophic lateral sclerosis is associated with a mutation in D-amino acid oxidaseMDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.Xenotransplantation: an overview of the field.Calcium micro-depositions in jugular truncular venous malformations revealed by Synchrotron-based XRF imagingEndothelial cells obtained from patients affected by chronic venous disease exhibit a pro-inflammatory phenotype.MDM2 non-genotoxic inhibitors as innovative therapeutic approaches for the treatment of pediatric malignancies.Intranasal administration of recombinant TRAIL down-regulates CXCL-1/KC in an ovalbumin-induced airway inflammation murine modelSerum TRAIL levels increase shortly after insulin therapy and metabolic stabilization in children with type 1 diabetes mellitus.Ultrastructure of internal jugular vein defective valves.Kinetic Profiles of Inflammatory Mediators in the Conjunctival Sac Fluid of Patients upon Photorefractive Keratectomy.GM-CSF exhibits anti-inflammatory activity on endothelial cells derived from chronic venous disease patients.Inhibitory effect of natural anti-inflammatory compounds on cytokines released by chronic venous disease patient-derived endothelial cells.The effectiveness of Robot-Assisted Gait Training versus conventional therapy on mobility in severely disabled progressIve MultiplE sclerosis patients (RAGTIME): study protocol for a randomized controlled trial.Modulation of circulating cytokine-chemokine profile in patients affected by chronic venous insufficiency undergoing surgical hemodynamic correction.State of the art of the therapeutic perspective of sorafenib against hematological malignancies.Heterogeneity of mesenchymal stromal cells in lymphoproliferative disorders.In vitro endothelial cell proliferation assay reveals distinct levels of proangiogenic cytokines characterizing sera of healthy subjects and of patients with heart failure.Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity.Redox signaling and oxidative stress: Cross talk with TNF-related apoptosis inducing ligand activity.Upregulation of SOCS-1 by Nutlin-3 in acute myeloid leukemia cells but not in primary normal cells.Soluble TRAIL is elevated in recurrent miscarriage and inhibits the in vitro adhesion and migration of HTR8 trophoblastic cells.Patients affected by metabolic syndrome show decreased levels of circulating platelet derived growth factor (PDGF)-BB.Association between circulatory levels of adipokines and bone mineral density in postmenopausal women.Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth.Establishment and characterization of xenografts and cancer cell cultures derived from BRCA1 -/- epithelial ovarian cancers.Differential effects of angiostatin, endostatin and interferon-alpha(1) gene transfer on in vivo growth of human breast cancer cells.Expression from cell type-specific enhancer-modified retroviral vectors after transduction: influence of marker gene stability.The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells.Inflammation and Cardiovascular Cross Talk in Ischemic Vascular Diseases.Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis.Low Circulating TRAIL Levels Are Associated with Increase of Resistin and Lipocalin-2/ngal Adipokines in Postmenopausal Women.Interferon-alpha gene therapy by lentiviral vectors contrasts ovarian cancer growth through angiogenesis inhibition.Inverse correlation between circulating levels of TNF-related apoptosis-inducing ligand and 17β-estradiol.TRAIL reduces impaired glucose tolerance and NAFLD in the high-fat diet fed mouse.The levels of circulating TRAIL at the onset of type 1 diabetes are markedly decreased in patients with ketoacidosis and with the highest insulin requirement.Oscillatory flow suppression improves inflammation in chronic venous disease.Gene-gene interactions among coding genes of iron-homeostasis proteins and APOE-alleles in cognitive impairment diseases.
P50
Q26766570-54EB8902-D383-478D-94F9-925D81E5140CQ28553937-16E4D4D4-C45A-4375-9CF3-2BB689BD8AABQ33763107-2B5F757D-8E4E-49BE-9BE6-60BFB49BA8C8Q33842154-B0F024FD-DF10-4596-BE7E-E20FFFB70564Q33869257-635D6820-C2D5-4369-B847-20542CEE598FQ34273379-1CC96B2D-1676-42A5-8DF7-22C563F86974Q34295152-118C7967-632E-460C-B749-3081B6567678Q34318454-CC82DCEA-848C-46C8-B5E2-54D58B6CAA9AQ34607597-8736F3EA-DC78-4CEC-809B-E524E0E8E154Q34704284-A3362938-2E68-4EA0-AFE3-77C2BE8BC46CQ36053378-19EFA7E6-06B3-46C5-A89E-6B9AC9455D6CQ36070905-4F28A425-5CCB-4491-9637-CB6785BEC16EQ36197930-88E0645E-81FD-490B-A60F-ABC5BD0182FAQ37353637-C695B834-1F91-46A5-A9B4-A49353964464Q37486658-AE98F430-877C-4AE5-9DB7-C8FF3ECEF3AAQ37671344-A3B920D0-BCA0-4BDA-8C6A-13668727C749Q37699909-6913FAEE-AC44-4D9E-8678-2851CF96028CQ38039184-D6095335-E920-476F-9047-F185B6564784Q38175715-0FE843E1-21A0-4145-9C4A-5396B9B34EDBQ38682384-12A93750-64BA-414B-B868-E9C2D3AE7033Q38812915-88621730-CEAB-4189-A4CD-D50D3BB969DBQ38968236-8511D476-6F79-4440-AA7C-6DD6877885DDQ39029498-0D80C053-3BFD-4308-B410-C11BBEE6CCB3Q39292824-4F653A88-A7A4-4A50-8CB3-B9AF688C1721Q39307209-286EFB77-DF5C-4519-8B16-F19A20279699Q39585713-F5BB4D03-0790-4069-90A2-99DD9707514AQ40195961-5F5CC46A-7D59-48D4-9FD5-2EFFE070D0BAQ40270449-BF62F423-B008-41ED-93E0-41E9609A17B8Q40722835-262D27D6-1ABF-4725-846F-F6ADAC8F46EAQ40748055-17B88BFF-1933-47AA-A8B4-8C58C62E3E26Q41708887-696B5FDE-F177-4661-8E88-8698120BFB2AQ42365130-05EF44A8-2103-4320-8074-63EBF44460B4Q42739960-32C068D5-D2C8-45E6-8EE0-06899934703BQ43379345-3CBF063F-78BD-404C-B399-2B3DCEC8F4B0Q45885618-E3EEEA6C-B3E9-431E-B3D8-9F2B71D53981Q46370349-B537A7A6-C2D9-4DBC-8637-311EDC034982Q47372528-128D8AD9-E3FA-4C3D-942E-CBE2AB32725BQ47832405-563A8A1B-152A-49CA-A157-9B2D01D230A3Q48681612-C1110C6E-2D6B-4EE5-AD76-1EE96B34DBF6Q50532074-154040F6-EB6C-4BE1-87E3-7029C478DAD3
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Veronica Tisato
@ast
Veronica Tisato
@en
Veronica Tisato
@es
Veronica Tisato
@nl
Veronica Tisato
@sl
type
label
Veronica Tisato
@ast
Veronica Tisato
@en
Veronica Tisato
@es
Veronica Tisato
@nl
Veronica Tisato
@sl
prefLabel
Veronica Tisato
@ast
Veronica Tisato
@en
Veronica Tisato
@es
Veronica Tisato
@nl
Veronica Tisato
@sl
P106
P1153
8052637800
P21
P31
P496
0000-0001-8448-066X